Harbour City

Harbour BioMed (HBM Holdings) is a global clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in oncology and immunology. The company leverages its proprietary Harbour Mice platform, which generates fully human monoclonal antibodies in both conventional (H2L2) and heavy chain-only (HCAb) formats. Its advanced pipeline includes batoclimab, a potential first-in-class FcRn inhibitor for autoimmune diseases, and tanfanercept for moderate-to-severe dry eye disease. Harbour BioMed also utilizes its HBICE bispecific antibody technology to develop next-generation immune cell engagers for cancer treatment. The company operates globally with major R&D centers in China, the United States, and the Netherlands.